Beta Cells Deficient for Renalase Counteract Autoimmunity by Shaping Natural Killer Cell Activity

Area of Science:

• Immunology
• Endocrinology
• Stem Cell Biology

Background:

• Type 1 diabetes (T1D) results from autoimmune destruction of pancreatic beta cells.
• Stem cell-derived beta cells offer potential for T1D cell replacement therapy.
• Autoimmunity remains a major obstacle for transplanted beta cell survival.

Approach:

• Investigated the role of Renalase (Rnls) gene inactivation in beta cell-mediated immune modulation.
• Examined the impact of Rnls deficiency on Natural Killer (NK) cell phenotype and function.
• Assessed the surface expression of immune checkpoints (CD47, Ceacam1) on Rnls-deficient beta cells.

Key Points:

• Loss of Rnls in beta cells promotes a regulatory NK cell phenotype, essential for inducing tolerogenic antigen-presenting cells.
• Rnls-deficient beta cells induce Tgfβ1, an anti-inflammatory cytokine, in NK cells independently of cell-cell contact.
• Surface expression of NK immune checkpoints CD47 and Ceacam1 is increased on Rnls-deficient beta cells, with CD47 upregulation linked to enhanced glucose metabolism.

Conclusions:

• Rnls inactivation in beta cells shapes autoimmunity by modulating NK cell responses.
• Genetically engineered beta cells with altered Rnls function offer a promising strategy for T1D cell replacement therapy.
• Understanding these mechanisms provides insights for developing effective T1D treatments.